USFDA gives nod for commercial production at Zydus Ahmedabad API unit
Ahmedabad: Pharma major Zydus Lifesciences has announced that the company has received Post Application Action Letter from the US Food and Drug Administration (USFDA) for the inspection conducted at the Ahmedabad API facility, confirming that the inspected facility has been considered as ready to commercially manufacture and supply the API. This facility underwent for-cause cGMP...
Ahmedabad: Pharma major Zydus Lifesciences has announced that the company has received Post Application Action Letter from the US Food and Drug Administration (USFDA) for the inspection conducted at the Ahmedabad API facility, confirming that the inspected facility has been considered as ready to commercially manufacture and supply the API.
This facility underwent for-cause cGMP surveillance and Pre-Approval Inspection for manufacturing of drug substances Enzylutamide from 14th to 22nd Dec 2023.
Enzalutamide is used for the treatment of prostate cancer.
Read also: USFDA issues 6 observations for Zydus Lifesciences Ahmedabad facility
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd